Q2 2025 Vericel Corp Earnings Call Transcript
Key Points
- Vericel Corp (VCEL) reported a 20% increase in total revenue for the second quarter, with gross margin expanding by over 400 basis points to 74%.
- The MACI segment achieved record second-quarter revenue of nearly $54 million, representing a 21% growth compared to the previous year.
- The company has trained approximately 600 surgeons for MACI Arthro, exceeding initial expectations and contributing to biopsy and implant growth.
- Epicel, part of the burn care franchise, saw a 40% increase in biopsies in the second quarter, marking the highest number since 2023.
- Vericel Corp (VCEL) ended the second quarter with approximately $164 million in cash and investments, maintaining a strong balance sheet with no debt.
- Despite strong metrics, Vericel Corp (VCEL) experienced a higher ratio of canceled cases due to patient health issues, impacting revenue.
- The company adjusted its burn care revenue guidance to align with recent run rates, indicating challenges in accurately predicting quarterly revenue.
- NexoBrid orders placed by specialty distributors were slightly lower than the prior quarter, affecting revenue comparisons.
- Operating expenses increased to $48.6 million, primarily due to increased headcount and costs related to the new facility.
- The company reported a net loss of $0.6 million for the quarter, although this was an improvement from the previous year's loss.
Good day and welcome to the Vericel Corporation's Second quarter 2025 earnings call. Today's conference is being recorded. At this time, I'd like to turn the conference over to Eric Burns, Vericel's Vice President of finance and investor relations. Please go ahead.
Thank you, operator, and good morning everyone. Joining me on today is Car Vericel's President and Chief Executive Officer Dominick Colangelo, and our Chief Financial Officer Joe Mara.
Before we begin, let me remind you that on today's call, we will be making forward-looking statements covered under the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ the choice and expectations and are described more fully in our findings with the SEC.
In addition, all forward-looking statements represent our views only as of today. It should not be relied upon as representing our views as of any subsequent date. Please note
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
